首页> 外文OA文献 >Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers
【2h】

Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers

机译:在BRCA1和BRCA2之外:意大利家庭中DNA修复途径基因的有害变体,乳腺/卵巢和胰腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The 5–10% of breast/ovarian cancers (BC and OC) are inherited, and germline pathogenic (P) variants in DNA damage repair (DDR) genes BRCA1 and BRCA2 explain only 10–20% of these cases. Currently, new DDR genes have been related to BC/OC and to pancreatic (PC) cancers, but the prevalence of P variants remains to be explored. The purpose of this study was to investigate the spectrum and the prevalence of pathogenic variants in DDR pathway genes other than BRCA1/2 and to correlate the genotype with the clinical phenotype. A cohort of 113 non-BRCA patients was analyzed by next-generation sequencing using a multigene panel of the 25 DDR pathways genes related to BC, OC, and PC. We found 43 unique variants in 18 of 25 analyzed genes, 14 classified as P/likely pathogenic (LP) and 28 as variants of uncertain significance (VUS). Deleterious variants were identified in 14% of index cases, whereas a VUS was identified in 20% of the probands. We observed a high incidence of deleterious variants in the CHEK2 gene, and a new pathogenic variant was detected in the RECQL gene. These results supported the clinical utility of multigene panel to increase the detection of P/LP carriers and to identify new actionable pathogenic gene variants useful for preventive and therapeutic approaches.
机译:5-10%的乳腺/卵巢癌(BC和OC)是遗传的,并且DNA损伤修复(DDR)基因BRCA1和BRCA2中的种系致病性(P)变体仅解释了这些病例的10-20%。目前,新的DDR基因与BC / OC和胰腺(PC)癌症有关,但P变形的患病率仍有待探索。本研究的目的是研究DDR途径基因的谱和致病变体的普遍性,并与临床表型相关联基因型。使用与BC,OC和PC相关的25 DDR途径基因的多烯烯面板,通过下一代测序分析113名非BRCA患者的群组。我们发现43个在25个分析的基因中的43种独特变体,14个分类为P / MOSPOLICOLIC(LP)和28,作为不确定意义(VUS)的变体。在14%的指数案件中确定有害变体,而VUS是在20%的证据中确定的。我们观察到CheK2基因中有害变体的高发病率,并在RECQL基因中检测到新的致病变体。这些结果支持多烯面板的临床效用,以增加P / LP载体的检测,并鉴定可用于预防性和治疗方法的新可操作的致病基因变体。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号